By now everyone has seen the two newest studies on GlaxoSmithKline's diabetes drug (rosiglitazone) Avandia and Takeda Pharmaceutical...

Sparked by today's apology by Bayer at its Trasylol FDA committee meeting, we thought it would be fun to round up a few recent mea culp...

A few days ago, we were talking with a small group of senior executives from one of the Big Pharmas. We were making the point that Big Pharm...

Autumn's here, and the NFL is back. IN VIVO Blog's contingent of Philadelphia Eagles fans is predictably feeling a little uneasy ab...

So Many Happy Faces! None are Running for President in 2008 The Medicare prescription drug benefit known as Part D has been an unmitigated ...

Capital hates a vacuum. In this case, the vacuum is Big Pharma’s late-stage pipeline. As deal prices rise for post-proof-of-concept products...

In previous posts, I have talked about the rising challenges facing the pharmaceutical and biotech industries stemming from FDA's credib...

Did you ever have a recurring nightmare? That is what Amgen Inc. and Johnson & Johnson want to avoid next week when another panel of exp...

There was little attention paid to last week's paper suggesting that PPAR delta agonists might be used to prevent the cardiovascular sid...

For those of you in the US, we hope you had a relaxing three-day weekend. Here are a few items you may have missed while sparing a thought f...